Podcasts about aplastic

This week, Jonathan is joined by Dr Shahram Kordasti, Associate Professor in Applied Cancer Immunopathology at King's College London, UK. In this episode, Dr Kordasti discusses the immunobiology of Myelodysplastic syndrome and Aplastic anaemia, the role of CD4+ T cells in myeloid malignancies, and how cutting-edge computational tools are enhancing treatment strategies.   Timestamps:  (00:00)-Introduction  (01:23)-Hodgkin's lymphoma origin   (04:21)- Immunobiology of diseases  (08:55)-Plasticity of T cells   (13:42)-Computational biology and multiomics for patient stratification  (21:00)-Standardising immune monitoring  (25:41)- Pretreatment with systemic agents  (27:55)- Myeloproliferative neoplasms  (31:48)-Synthetic data generation   (36:22)-Exciting developments on the horizon   (39:16)-Three wishes for healthcare  

Brittany is the mother of a 4 1/2-year-old boy named Callan. Their son was experiencing bloody noses at a young age. After a week in the hospital, Callan was diagnosed with Aplastic anemia, which is a rare but serious blood condition that occurs when your bone marrow cannot make enough new blood cells for your body to work. At the same time, he was also diagnosed with Klinefelter syndrome.

Morag Griffin, Haematology Consultant, Leeds University Teaching Hospitals, UK, joins Jonathan to discuss rare haematological conditions, such as aplastic anaemia and paroxysmal nocturnal haemoglobinuria, as well as their treatments. They also discuss how vaccination response is affected by these diseases. Use the following timestamps to navigate the topics discussed in this episode: (00:00)-Introduction (01:13)-What led Griffin into haematology (02.00)-How Griffin's Master's degree in leadership helped her throughout her career (03.10)-Paroxysmal nocturnal haemoglobinuria (PNH) (09.13)-Griffin's research on biomarkers and laboratory assessments for monitoring the treatment of patients with PNH (12:44)-Aplastic anaemia (16:43)-Importance of international collaboration (19:34)-How aplastic anaemia and PNH affect vaccination responses (23:45)-Histiocytic disease (26:23)-Future research in haematology (29:02)-Three wishes for the future of healthcare

Overview Hemoglobin Normal Value Range Pathophysiology Special considerations Elevated hemoglobin Decreased hemoglobin Nursing Points General Normal value range Males – 13.5-16.5 g/dL Females – 12.0 – 15.0 g/dL Pathophysiology Protein attached to red blood cell Iron based protein 4 groups 2 alpha 2 beta Has a high affinity (attraction) for oxygen Oxyhemoglobin Has oxygen attached Deoxyhemoglobin Oxygen has been released Oxyhemoglobin Dissociation Curve Oxygen saturation Shift to the right Partial pressure is higher HGB attraction to oxygen is lower Oxygen becomes less “sticky” and wants to be released Causes ↓pH ↑pCO2 ↑Temperature Shift to the left Partial pressure is lower HGB attraction is higher Oxygen wants to stay “stuck” to HGB Causes ↑pH ↓pCO2 ↓Temperature Special considerations Submit in lavender top tube Be cautious with phlebotomy technique Reduce hemolysis with proper tubing and syringes Elevated HGB values Polycythemia vera Treatments Blood letting Increased water intake Some medications Dehydration Lung disease Pulmonary fibrosis COPD Certain medical therapies EPO supplementation Decreased HGB values Thalassemia Blood loss Sickle Cell anemia Aplastic anemia Cancers Assessment Assess for signs of anemia Tachycardia Fatigue Shortness of breath Decreased SaO2 Pallor Therapeutic Management Blood transfusions as necessary Treat primary cause of anemia Nursing Concepts Lab Values Oxygenation

Make A Wish foundation: https://wish.org/Aplastic anemia: https://www.nhlbi.nih.gov/health/anemia/aplastic-anemia#:~:text=Aplastic%20anemia%20is%20a%20rare,way%20to%20prevent%20aplastic%20anemia.Maitreya: https://share-international.org/summary-for-new-readers/#maitreya8217s-emergenceAnthroposophic Medicine: http://www.anthromed.de/en/anthromed/anthroposophic.medicine/#:~:text=Anthroposophic%20Medicine%20is%20an%20integrative,the%20human%20being%20in%20body%2CWaldorf school : https://en.wikipedia.org/wiki/Waldorf_educationHomoeopathy: https://www.homeopathy-ich.org/about-homeopathyShare International magazine: https://share-international.org/resources/magazine/Benjamin Creme: https://share-international.org/for-news-media/who-was-benjamin-creme/Elisa's letter to Share International: https://share-international.org/resources/magazine/november-2022/#readers-letters-a-selection

$5 Q-BANK: https://www.patreon.com/highyieldfamilymedicine Intro 0:30, Sickle cell anemia 1:34, Thalassemia 9:03, Hereditary spherocytosis 15:36, G6PD deficiency 17:38, Pyruvate kinase deficiency 19:27, Microangiopathic hemolytic anemia 20:08, Autoimmune hemolytic anemia 24:56, Paroxysmal nocturnal hemoglobinuria 26:59, Blood transfusion reactions 28:31, Drug-induced hemolysis 30:05, Malaria 30:42, Babesiosis 31:47, Iron deficiency anemia 32:34, Megaloblastic anemia 35:34, Lead poisoning 37:59, Porphyria 39:07, Sideroblastic anemia 40:01, Aplastic anemia 41:23, Polycythemia 45:24, Methemoglobinemia 46:34, Carbon monoxide poisoning 47:56, Hemophagocytic lymphohistiocytosis 48:48, Practice questions 49:34

Get a free nursing lab values cheat sheet at NURSING.com/63labs   What is the Lab Name for Hemoglobin (Hbg) Lab Values? Hemoglobin   What is the Lab Abbreviation for Hemoglobin? Hbg   What is Hemoglobin in terms of Nursing Labs? Hemoglobin (Hbg), an iron containing compound, is the main protein in Red Blood Cells (RBCs). It enables oxygen and carbon dioxide (CO2) to bind to RBCs for transport throughout the body.   What is the Normal Range for Hemoglobin? Male: 13.5 – 16.5 g/dL | Female: 12.0 – 15.0 g/dL   What are the Indications for Hemoglobin? Identify: Bleeding disorders Anemia Blood loss     What would cause Increased Levels of Hemoglobin? Erythrocytosis Polycythemia Vera Shock Dehydration Severe burns Chronic Obstructive Pulmonary Disease (COPD) Congenital Heart Disease   What would cause Decreased Levels of Hemoglobin? Anemia Blood Loss Bone Marrow Disorders: Leukemia Lymphoma Multiple myeloma Aplastic anemia Severe burns Hyperthyroidism Renal disease Systemic Lupus Erythematosus (SLE)

Get a free nursing lab values cheat sheet at NURSING.com/63labs   What is the Lab Name for Hematocrit (Hct) Lab Values? Hematocrit   What is the Lab Abbreviation for Hematocrit? Hct   What is Hematocrit in terms of Nursing Labs? Hematocrit (Hct) is the percentage of the blood that is made up of packed Red Blood Cells (RBCs). A hematocrit level of 40% indicates that there are 40 mL packed red blood cells in 100 mL of blood.   What is the Normal Range for Hematocrit? Male: 41 – 50% | Female: 36 – 44%   What are the Indications for Hematocrit? Identify: Anemia Bleeding Bleeding disorder Fluid imbalances   What would cause Increased Levels of Hematocrit? Erythrocytosis Polycythemia Vera Shock Dehydration Chronic Obstructive Pulmonary Disease (COPD) Congenital Heart Disease   What would cause Decreased Levels of Hematocrit? Anemia Blood loss Bone marrow disorders: Leukemia Lymphoma Hodgkin disease Multiple myeloma Aplastic anemia Hyperthyroidism Renal disease Rheumatoid arthritis (RA)

If have not already done so, please head to the link below and make sure to download our podcast reflection sheets. They're absolutely free! https://artofcoaching.com/podcastreflections/   Imagine this; you wake up alone in a hospital. Every time you touch your skin, no matter how gently, you bruise. To the point, if you roll over wrong or you scratch an itch, or you rub your eye, you may wake up the next day with hundreds of bruises. Not only that, but you're also told by doctors and surgeons that you have a disease, an affliction that only one in a million people will ever get. How would you act? What goes through your mind? If you've ever spent time in a hospital, you know what that environment feels like. You know the smell. You know the sounds, and the footprints. You see the urgency of doctors and nurses, the beeps, the clangs, and the bangs.  There's a deafening silence while you sit in your own head thinking, "where am I, and what's going to happen?". Everyone, our guest today has an extraordinary story, and everything I've just described is a part of it. Brendon Rearick came back and is in remission from a very rare condition called Aplastic anemia. I'm going to let him tell this story, but I encourage you to listen up. As with every episode, please understand that nothing in these podcast episodes is just for strength coaches. Nothing is for people in any vacuum type situation. The lessons we experience in our lives are the very things that shape our outcome and our profession and our personal lives. So take heed, listen, and write notes. There's a lot of great stuff coming your way on today's episode. Brendon's personal mission is to spread the positive by-products of coaching and movement as far as he can using strength and conditioning as his platform. With a degree in Kinesiology from the University of Massachusetts Amherst, Brendon got his start at Mike Boyle Strength and Conditioning (MBSC) in Woburn, MA. The growth-focused environment at MBSC motivated Brendon in a way he had never experienced. Over a few short years he progressed to become the Program Director and earned his massage therapy license. Soon thereafter, he started an education company with four co-workers – Certified Functional Strength Coach. In five years, CFSC has certified over 6,500 trainers in over 50 countries. Now a California resident, Brendon travels and coaches often for Certified Functional Strength Coach, and has recently become an active speaker at the Perform Better summit conferences. His next venture will be opening a gym Train Smarter and Harder with his wife Jenny in the beginning of 2020. With an inexhaustible drive to learn more, practice his craft, and be the best version of himself, Brendon dedicates his free time to continuing education, dancing with his 3-year old daughter, reading, writing, and enjoying the outdoors. Reach out to Brendon: Via e-mail: BrendonRearick@gmail.com   Join our exclusive Facebook group of fellow Art of Coaching Podcast listeners and have your voice heard!   Don't forget to check-out and download our new free resources.   Podcast Reflection Sheets: Click Here   How to Find a Mentor Guide: Click Here   Sign up for my course: Sign Up Now!   Follow me on social media:   Via Instagram: @coach_BrettB   Via Twitter: @coach_BrettB   Subscribe to my YouTube channel here   Learn More About My Courses, Clinics, and Live Events At: www.ArtofCoaching.com  

As promised, this week chloramphenicol begins to show some serious problems. Dr. Albe Watkins and Edgar Elfstrom both lost children, and push for new restrictions on the drug. They are at least somewhat successful, but the mid twentieth century is a different time from now, and it will take more tragedy before we begin to see bigger change. Website: http://thehistoryofmedicine.buzzsprout.com/E-mail: thehistoryofmedicinepodcast@gmail.comFacebook: https://www.facebook.com/TheHistoryOfMedicine/Transcripts and Sources here!

In the final episode of season three, our guest Alexandra tells us about being diagnosed with a rare blood disease and her experience having a bone marrow transplant.  Follow us on Instagram, Twitter, and Facebook:@beingtherepod www.patreon.com/beingtherepod More shows from PODCAST JUKEBOX: Disability After Dark | Queers Next Door |  Will Sean Podcast? | The Goth Librarian Podcast Drinks with God | ProudToBeKinky | NO LOVE LOST Off the Cuffs: a Kink and BDSM podcast Being There is Produced and Engineered by:Sean M. Corkery (OCP Productions, LLC) Music:510 (intro) 510 Reprise (outro)Written by Sean M. Corkery Performed by Old Saws Recorded and Engineered by Rob Tav

Benzene is a chemical widely used in a number of industries and products. Exposure to the chemical has been linked to Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), lymphomas and aplastic anemia. Many of these cases involving benzene exposure link back to the workplace. Ringler Radio host Larry Cohen and co-host, Keith Christie talk with attorney John Tomlinson, from the Beasley Allen law firm, about benzene exposure, litigation, and how exposure to benzene can be controlled, reduced or prevented.

Benzene is a chemical widely used in a number of industries and products. Exposure to the chemical has been linked to Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), lymphomas and aplastic anemia. Many of these cases involving benzene exposure link back to the workplace. Ringler Radio host Larry Cohen and co-host, Keith Christie talk with attorney John Tomlinson, from the Beasley Allen law firm, about benzene exposure, litigation, and how exposure to benzene can be controlled, reduced or prevented.

Dr Townsley talks to ecancertv at ASH 2015 about adding eltrombopag to standard immunosuppressive therapy for aplastic anaemia in previously untreated patients. Eltrombopag was originally developed to increase platelet counts in patients with chronic immune thrombocytopenia (ITP) but it was found to also increase white and red cell counts. This was logical in hindsight, Dr Townsley observes in the interview. Although it is licensed for the treatment of refractory aplastic anaemia in Europe, eltrombopag is only approved for use in ITP in the USA and further study data were needed. The study presented by Dr Townsley aimed to provide evidence that eltrombopag could be used in aplastic anaemia setting and included 92 patients with the rare disease. Results showed a clear benefit of adding eltrombopag to standard immunosuppressive therapy of horse antithymocyte globulin (hATG) and cyclosporine versus the immunosuppressive therapy alone. Haematological overall response rates were 80% and 85% at 3 and 6 months, respectively, and highest if eltrombopag was given on the first day of immunosuppressive therapy as opposed to 2 weeks after and continued for either 3 or 6 months. Overall survival is 99%, Dr Townsley highlights, as only one patient has died while in the study to date but follow up is short.

Let's look at what happens when the stem cells or progenitor cells start dysfunctioning.

Interview with Gerard Socie, from the Hopital Saint-Louis, Paris, France. Prof. Socie discusses the topic 'Severe aplastic anemia Fanconi Anemia'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Gerard Socie, from the Hopital Saint-Louis, Paris, France. Prof. Socie discusses the topic 'Severe aplastic anemia Fanconi Anemia'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Jakob Passweg, Prof. Hematology at Basil University, Switzerland. Prof. Passweg discusses the topic 'Severe Aplastic Anemia'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Jakob Passweg, Prof. Hematology at Basil University, Switzerland. Prof. Passweg discusses the topic 'Severe Aplastic Anemia'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Neil Young. Chief of the Hematology Branch of the NHLBI of the NIH, Bethesda, USA. Prof. Young discusses the topic 'Pathology of Aplastic Myeoleukemia'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Interview with Neil Young. Chief of the Hematology Branch of the NHLBI of the NIH, Bethesda, USA. Prof. Young discusses the topic 'Pathology of Aplastic Myeoleukemia'.The interview is led by Shaun McCann, Chair of EHATol Unit, Member of EHA Education Committee.

Aplastic crisis is an unusual feature of systemic lupus erythematosus (SLE). We report the case of a 54-year-old woman presenting with both (extravascular) Coombs-positive hemolytic anemia and laboratory findings of bone marrow hyporegeneration with concomitant severe neutropenia. A bone marrow biopsy confirmed aplastic crisis. Diagnostic work-up revealed soaring titers of autoantibodies (anti-nuclear, anti-double-stranded DNA, anti-cardiolipin-IgM, and anti-beta 2-glykoprotein-IgM antibodies), indicating a connective tissue disease as the most plausible reason for bone marrow insufficiency. As the criteria for SLE were fulfilled, we initiated an immunosuppressive therapy by steroids, which led to a rapid complete hematologic and clinical remission in our patient. In this case, we could report on one of the rare cases of SLE-induced aplastic crisis showing that this condition can be entirely reversed by immunosuppressive treatment and that SLE-induced aplastic crisis yields a good prognosis. In conclusion, in a case of aplastic crisis, physicians should be aware that SLE can be a rare cause that is accessible to specific treatment.